Rocket Lab announced a $90 million U.S. Space Force contract on Thursday to design, build, and operate two GEO satellites hosting the Heimdall space domain awareness payload - sensors that track objects in geostationary orbit. The deal transitions the program from prototyping to operational delivery.
The headline is clean. The factor stack behind it is less so.
The question isn't whether the contract validates the business. It's whether the numbers that built the stock to a $51.8 billion market cap have kept pace with the narrative, or whether one factor is doing all the work while the others trail behind.
The growth story is the engine. The rest is ballast.
Q1 2026 revenue hit $200.3 million, up 63% from a year ago, clearing the top end of Rocket Lab's own $185-to-$200 million guidance range. It's the first time the company has cleared $200 million in a single quarter. Net loss narrowed to $0.07 per share, which is still a loss but a thinner one on a revenue base that's growing this fast. The total backlog sits above $1.07 billion.
On growth, the grade is A. Revenue up 63% in a quarter, launching cadence accelerating, and the Space Systems segment - satellites, sensors, components - now carrying real weight alongside the Electron launch services business. The $90 million GEO contract adds to that. It's not a single-event blip; it's part of a contract stack that's compounding.
But a stock cannot run on growth alone when the valuation factor is this detached.
Valuation: F. You're paying 37.6 times trailing sales.
At roughly $125 per share and a $52 billion market cap, Rocket Lab trades at 37.6x annualized revenue. The P/E ratio is negative - the company is not yet profitable on a GAAP basis, and the multiple sits at -385, which is a mechanical artifact of dividing price by a tiny net loss rather than a real valuation signal.
What matters is the P/S. A 37.6x sales multiple means the market is pricing in years of sustained high-teens-to-20% revenue growth, successful Neutron ramp, and continued government contract wins - and assuming none of those assumptions break. That is a lot of future perfection baked into today's price.
Compare that to the broader aerospace-and-defense sector, where even the fastest-growing names rarely command 15x sales on a sustained basis. Rocket Lab isn't priced like a defense contractor. It's priced like a high-multiple tech growth story that hasn't yet earned the right to one.
Profitability: D-. Improving, but the grade says what it says.
The narrowing net loss is the directionally right signal. Adjusted EBITDA is climbing as launch cadence increases and Space Systems revenue scales. But profitability here is still a trajectory, not a reality. At this stage, the company is investing heavily in Neutron development - the medium-lift rocket that's been delayed to no earlier than Q4 2026 - and those R&D costs are the difference between a thin loss and real earnings.
In our book, a D- on profitability with A-grade growth is the classic GARP tension: growth investors tolerate it because the revenue inflection is real, but value discipline says you're carrying execution risk on both the Neutron timeline and the margin path.
Momentum: A+. Including a 34% single-day surge on the Q1 earnings report in early May.
The stock has climbed from roughly $85 in mid-April to the $125-to-$135 range, with the Q1 earnings pop doing the heavy lifting. Momentum is strong, and momentum confirms the market's bid is real. It doesn't confirm the thesis is complete.
The Neutron variable
Neutron is the optionality layer. It's the medium-lift rocket that would let Rocket Lab compete directly in the larger satellite and government launch market - a market currently dominated by SpaceX and United Launch Alliance, which together won nearly $1.1 billion in Space Force launch contracts for 2026. A Q4 2026 first flight is the current target, but the program has already slid from earlier dates after a test setback earlier this year.
If Neutron launches on time and performs, the $52 billion market cap starts looking defensible. If it delays again or burns through cash without a reliable cadence, the growth multiple compresses because the primary catalyst for mid-market launch revenue disappears from the near-term view.
What the stack says to do
This is a growth sleeve stock, not an income stock, not a value stock, not a barbell hedge. It belongs in the portion of the portfolio allocated to companies that have revenue acceleration and government contracting momentum but carry valuation stretch and execution risk.
If you already own it, a cooling from Strong Buy to Hold on the valuation side isn't a signal to sell - it's a signal that the risk/reward has moved from asymmetric to neutral. Hold is not sell. The factor that drove the move - growth - is still intact. The factor creating drag - valuation - has caught up.
If you're looking to add, the entry works if you're comfortable with a barbell approach: pair this with a dividend name, a REIT, or a durable cash-flow business that anchors the other side of the portfolio. That's how you manage a 37x-sales position without betting the whole account on a Q4 rocket launch that has already slipped once.
The trigger that changes the rating upward is profitability - the first GAAP-profitable quarter, or a Neutron flight that turns the optionality layer into revenue. The trigger that changes it downward is a Neutron delay beyond Q4 2026 or a quarter where revenue growth drops below the 30% mark without a compensatory margin improvement. Watch those two signals. The contract is real. The math around it is what decides the trade.